Pieris Pharmaceuticals(PIRS) - 2022 Q4 - Earnings Call Presentation

12 31 moderate asthmatics controlled on standard-of-care therapy (medium dose ICS with LABA) were dosed twice daily over four weeks randomized across two dose levels and placebo (1:1:1) Safety review performed of the following (compared to placebo): Changes in laboratory markers (immune biomarkers, clinical chemistry, and hematology) Pharmacokinetics Potential Large Market Opportunity in Moderate-to-Severe Asthma not Addressed by ICS/LABA before Injectable Biologics 3 5 INTERMITTENT AND MILD MILD-TO-MODERAT ...